Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Sorafenib plus hepatic arterial infusion chemo does the job in advanced liver cancer

02 Jul 2020

Treatment with the combination of sorafenib plus hepatic arterial infusion chemotherapy (SoraHAIC) appears to be effective and well tolerated in patients with advanced hepatocellular carcinoma (HCC), according to the results of a meta-analysis.

Researchers searched multiple online databases for relevant studies examining the clinical utility of the combination therapy in advanced liver cancer. The search yielded five studies for inclusion in the meta-analysis. The major outcomes examined were overall response rate, overall survival, progressive disease, and adverse events. These outcomes were compared between SoraHAIC and sorafenib monotherapy.

The total population comprised 726 patients. Pooled data showed that compared with sorafenib alone, SoraHAIC produced a significant improvement in overall response (risk ratio [RR], 3.08,  95 percent confidence interval [CI], 1.38–6.89; p=0.006) and complete response (RR, 5.84, 95 percent CI, 1.85–18.45; p=0.003) rates.

The combination therapy also yielded substantial survival gains, with the median overall survival prolonged relative to sorafenib monotherapy (hazard ratio, 0.59, 95 percent CI, 0.35–1.00; p=0.05).

However, safety outcomes were better with the monotherapy. The risk of adverse events, such as anaemia, neutropaenia, and thrombocytopaenia, was markedly higher among patients in the combination group (p<0.05).

The present data indicate that SoraHAIC is useful for treating advanced HCC. However, additional large-scale randomized controlled trials should be conducted to establish the clinical benefit of the combination.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.